Peptides
EPO (Erythropoietin)
Also called Erythropoietin · Epoetin · EPO
EPO stimulates red-blood-cell production. In medicine it treats specific forms of anemia; endurance athletes have misused it hoping to carry more oxygen, but raising blood counts also raises serious clotting and cardiovascular concerns.
Dosage & duration
US adult chronic-kidney-disease label context only; not an endurance protocol.
Epogen, adults with CKD
Product label- Dose
- 50–100 Units/kg starting range
- How often
- Three times weekly, intravenous or under the skin
- How long
- Ongoing, adjusted to hemoglobin and transfusion needs
Other indications use different regimens; eligibility, monitoring and dose adjustments are essential.
Sources: 1
Do not translate anemia treatment into a performance cycle or a target hematocrit.
Endurance and blood counts
More oxygen-carrying capacity is only part of the story
Why it attracts interest
-
Red blood cells
EPO stimulates their production; these cells carry oxygen.
Why the risk matters
-
Clots and circulation
The label warns about blood clots, heart attack and stroke.
Performance is separate The cycling trial improved some laboratory measures without improving every road-performance measure.
Why it is associated with endurance
Red blood cells carry oxygen, which makes EPO attractive in endurance sport. A controlled cycling trial improved some laboratory maximum-effort measures without improving all real-world race measures. A higher blood count is not a guaranteed faster finish.
Medical treatment has a different goal
Epoetin treatment aims to reduce transfusion need in selected conditions, using the lowest effective dose and blood-test adjustment. It is not a plan to push a healthy person’s hemoglobin upward.
Why a curve is not a blood-count forecast
The drug’s concentration changes faster than the red-cell response. A plotted line cannot predict hematocrit, oxygen delivery or clot risk. Dehydration and exercise further complicate interpreting blood counts.
The major risks
The label warns about death, heart attack, stroke and blood clots, along with tumour-related risks in some cancer settings. A “normal” single blood test or an athletic cut-off is not a guarantee of safe misuse.
Model details: EPO (Erythropoietin) · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
The historical 9.6 h value falls inside the 4–13 h IV CKD label range, but is not a verified SC estimate. SC timing varies with dose and population; label Tmax is 5–24 h.
One 1 legacy units input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 9.6 hours
- Absorption half-life assumed
- 2.4 hours
- Reference amount for the relative scale
- 1 legacy units
- Saved numerical amounts retain their original values. No conversion to milligrams or IU is established.
- Absorption half-life is assumed to be one quarter of the slower timescale (2.4 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Do not reinterpret legacy stored amounts as mass or IU.
- An IU conversion requires a separately verified serialization and migration contract.
- One SC curve cannot represent all CKD, cancer, dialysis and healthy populations.
Saved amounts retain their original numeric encoding. A supported conversion to milligrams or IU has not been established; these are legacy units for a relative timing scenario.
- EPOGEN label 12.3
The label gives IV half-lives of 4–13 h in CKD and SC peaks at 5–24 h. Studies comparing 150 IU/kg three times weekly with 40,000 IU weekly found different exposures and clearance; the anemic-cancer SC terminal average was about 40 h.
epo-relative-timing-2026-10 · version 1
Common questions
Does the EPO curve show my hematocrit?
No. Drug exposure and the delayed red-cell response are different; a blood count requires measurement.
Is a low dose safe for sport?
The cited evidence does not establish a safe performance-enhancing regimen or a protective blood-count threshold.
Sources Labels, studies and notes behind this guide
Catalog evidence: Human clinical trials. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Medical purpose
- Treatment is tied to diagnosis and monitored response.
- Performance interest
- Does not guarantee better race performance.
- Main risk
- A chart cannot estimate your risk.
- 1. Epogen US prescribing information
Adult CKD starting context 50–100 Units/kg three times weekly, clinician-adjusted. Boxed cardiovascular/thrombotic/tumour warnings; not an athletic schedule.
- 2. Randomized EPO cycling-performance trial
Well-trained nonprofessional male cyclists; laboratory maximal outcomes and road performance differed.
- 3. EPO and exercise coagulation study
Controlled athlete study of endothelial activation and clotting markers; not a personal safe-hematocrit threshold.
- 4. EPOGEN label 12.3
The label gives IV half-lives of 4–13 h in CKD and SC peaks at 5–24 h. Studies comparing 150 IU/kg three times weekly with 40,000 IU weekly found different exposures and clearance; the anemic-cancer SC terminal average was about 40 h.
- 5. EPOGEN current prescribing information
Approved anemia contexts, activity Units, IV/SC differences, delayed red-cell response and boxed cardiovascular/thrombosis/tumor warnings; label viewed October 2026.
Keep reading
Related compounds and examples
Related compounds
ACE-031
ACE-031 muscle-growth research: trial doses, myostatin claims and why bigger muscle measures are not enough.
AICAR
AICAR for endurance: where the exercise-pill claim comes from, reported amounts and comparison with Cardarine.
SLU-PP-332
SLU-PP-332 draws interest for fat loss and endurance—the “exercise mimetic” idea. Mouse studies showed exercise-like metabolic changes, but they do not show that it replaces training or produces the same results in people. Human online experiments remain uncontrolled reports.